Novel peptide nanoparticle–biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness
M Grozdanovic, KG Laffey, H Abdelkarim… - Journal of Allergy and …, 2019 - Elsevier
Background Chemokine signaling through CCR3 is a key regulatory pathway for eosinophil
recruitment into tissues associated with allergic inflammation and asthma. To date, none of
the CCR3 antagonists have shown efficacy in clinical trials. One reason might be their …
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltd
www.pepmic.com
M Grozdanovic, KG Laffey, H Abdelkarim… - Journal of Allergy and …, 2019 - Elsevier
Background Chemokine signaling through CCR3 is a key regulatory pathway for eosinophil
recruitment into tissues associated with allergic inflammation and asthma. To date, none of
the CCR3 antagonists have shown efficacy in clinical trials. One reason might be their …
recruitment into tissues associated with allergic inflammation and asthma. To date, none of
the CCR3 antagonists have shown efficacy in clinical trials. One reason might be their …
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论